{
    "name": "bleomycin",
    "comment": "Rx",
    "other_names": [
        "Blenoxane"
    ],
    "classes": [
        "Antineoplastics",
        "Antibiotic"
    ],
    "source": "https://reference.medscape.com/drug/bleomycin-342113",
    "pregnancy": {
        "common": [
            "Pregnancy Category: D",
            "Lactation: It is not known whether the drug is excreted in milk. Because of the potential for serious adverse reactions in nursing infants, it is recommended that nursing be discontinued by women receiving bleomycin therapy."
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Lactation: It is not known whether the drug is excreted in milk. Because of the potential for serious adverse reactions in nursing infants, it is recommended that nursing be discontinued by women receiving bleomycin therapy."
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [
                "Severe idiosyncratic reactions including hypotension, confusion, fever, chills, and wheezing occurring usually after the first or second dose have been reported.",
                "Monitoring is very important after administering these doses.",
                "Pneumonitis that progresses to pulmonary fibrosis is the most severe toxicity reported. Risk increases in elderly persons and with doses >400 units.",
                "The drug should be administered under the supervision of an experienced cancer chemotherapy physician."
            ],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity",
                "Concomitant use of bleomycin with brentuximab because of pulmonary toxicity"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Use caution in renal impairment",
                "Hepatic toxicity reported",
                "Use caution when administering oxygen during surgery (increases risk of pulmonary toxicity)",
                "Risk of pulmonary fibrosis (at lower doses if used with other antineoplastics)",
                "Avoid pregnancy"
            ],
            "specific": []
        }
    },
    "interactions": [
        {
            "classification_type": "Contraindicated",
            "interaction_with": "brentuximab vedotin",
            "description": {
                "common": "brentuximab vedotin and bleomycin both increase  Other (see comment). Contraindicated. Contraindicated because of increased risk of pulmonary toxicity. "
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "adenovirus types 4 and 7 live, oral",
            "description": {
                "common": "bleomycin decreases effects of adenovirus types 4 and 7 live, oral by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Immunosuppressives may diminish therapeutic effects of vaccines and increase risk of adverse effects (increased risk of infection). Live-attenuated vaccines should be avoided for at least 3mo after cessation of immunosuppressive therapy."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "influenza virus vaccine quadrivalent, adjuvanted",
            "description": {
                "common": "bleomycin decreases effects of influenza virus vaccine quadrivalent, adjuvanted by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Immunosuppressive drugs may reduce the immune response to influenza vaccine."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "influenza virus vaccine trivalent, adjuvanted",
            "description": {
                "common": "bleomycin decreases effects of influenza virus vaccine trivalent, adjuvanted by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Immunosuppressive drugs may reduce the immune response to influenza vaccine."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "palifermin",
            "description": {
                "common": "palifermin increases toxicity of bleomycin by Other (see comment). Avoid or Use Alternate Drug. \nComment: Palifermin should not be administered within 24 hrbefore, during infusion of, or within 24 hr after administration of antineoplastic agents. Coadministration of palifermin within 24 hr of chemotherapy resulted in increased severity and duration of oral mucositis."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cholera vaccine",
            "description": {
                "common": "bleomycin decreases effects of cholera vaccine by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Immunosuppressive therapies, including irradiation, antimetabolites, alkylating agents, cytotoxic drugs and corticosteroids (used in greater than physiologic doses), may reduce the immune response to cholera vaccine."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dengue vaccine",
            "description": {
                "common": "bleomycin decreases effects of dengue vaccine by immunosuppressive effects; risk of infection. Use Caution/Monitor. Immunosuppressive therapies (eg, irradiation, antimetabolites, alkylating agents, cytotoxic drugs, corticosteroids [greater than physiologic doses]) may reduce immune response to dengue vaccine."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ethotoin",
            "description": {
                "common": "bleomycin decreases levels of ethotoin by increasing metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fosphenytoin",
            "description": {
                "common": "bleomycin decreases levels of fosphenytoin by increasing metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "meningococcal group B vaccine",
            "description": {
                "common": "bleomycin decreases effects of meningococcal group B vaccine by pharmacodynamic antagonism. Use Caution/Monitor. Individuals with altered immunocompetence may have reduced immune responses to the vaccine."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ofatumumab SC",
            "description": {
                "common": "ofatumumab SC, bleomycin.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor. Consider the risk of additive immune system effects when coadministering immunosuppressive therapies with coadministration. When switching from therapies with immune effects, take into account the duration and mechanism of action of these therapies when initiating ofatumumab SC."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "olaparib",
            "description": {
                "common": "bleomycin and olaparib both increase  pharmacodynamic synergism. Use Caution/Monitor. Coadministration with other other myelosuppressive anticancer agents, including DNA damaging agents,  may potentiate and prolongate the myelosuppressive toxicity. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "oxaliplatin",
            "description": {
                "common": "oxaliplatin and bleomycin both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor. Use of oxaliplatin with concomitant immunosuppressants or with impaired immune systems may increased risk for serious infections."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "phenytoin",
            "description": {
                "common": "bleomycin decreases levels of phenytoin by increasing metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "siponimod",
            "description": {
                "common": "siponimod and bleomycin both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor. Caution if coadministered because of additive immunosuppressive effects during such therapy and in the weeks following administration. When switching from drugs with prolonged immune effects, consider the half-life and mode of action of these drugs to avoid unintended additive immunosuppressive effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tenofovir DF",
            "description": {
                "common": "bleomycin increases levels of tenofovir DF by decreasing renal clearance. Use Caution/Monitor. Potential for increased toxicity. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "trastuzumab",
            "description": {
                "common": "trastuzumab, bleomycin.\nEither increases toxicity of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor.  Neutropenia or febrile neutropenia incidence were increased when trastuzumab was coadministered with myelosuppressive chemotherapy. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "trastuzumab deruxtecan",
            "description": {
                "common": "trastuzumab deruxtecan, bleomycin.\nEither increases toxicity of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor.  Neutropenia or febrile neutropenia incidence were increased when trastuzumab was coadministered with myelosuppressive chemotherapy. ."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Mucocutaneous toxicity including rash",
            "percent": "50"
        },
        {
            "name": "erythema",
            "percent": "25-50"
        },
        {
            "name": "hyperpigmentation",
            "percent": "30"
        },
        {
            "name": "urticaria",
            "percent": "30"
        },
        {
            "name": "Febrile reactions",
            "percent": "10"
        },
        {
            "name": "acute",
            "percent": "10"
        },
        {
            "name": "Mucositis",
            "percent": "1-10"
        },
        {
            "name": "Stomatitis",
            "percent": "1"
        },
        {
            "name": "Interstitial pneumonitis",
            "percent": null
        },
        {
            "name": "Pulmonary fibrosis",
            "percent": null
        },
        {
            "name": "Anorexia",
            "percent": null
        },
        {
            "name": "Weight loss",
            "percent": null
        },
        {
            "name": "Rales",
            "percent": null
        },
        {
            "name": "Tachypnea",
            "percent": null
        },
        {
            "name": "Alopecia",
            "percent": null
        },
        {
            "name": "Fatal pulmonary fibrosis",
            "percent": null
        },
        {
            "name": "Confusion",
            "percent": null
        },
        {
            "name": "Shivering",
            "percent": null
        },
        {
            "name": "Anphylactoid reactions",
            "percent": null
        },
        {
            "name": "Onycholysis",
            "percent": null
        },
        {
            "name": "Pruritus",
            "percent": null
        },
        {
            "name": "Skin thickening",
            "percent": null
        },
        {
            "name": "Scleroderma",
            "percent": null
        },
        {
            "name": "Nausea",
            "percent": null
        },
        {
            "name": "Malaise",
            "percent": null
        },
        {
            "name": "Myocardial infarction",
            "percent": null
        },
        {
            "name": "Hypotension",
            "percent": null
        },
        {
            "name": "Cerebral vascular accident",
            "percent": null
        },
        {
            "name": "Raynaud",
            "percent": null
        },
        {
            "name": "s phenomenon",
            "percent": null
        },
        {
            "name": "Fatal pulmonary fibrosis",
            "percent": null
        },
        {
            "name": "Hepatotoxicity",
            "percent": null
        },
        {
            "name": "Renal toxicity",
            "percent": null
        },
        {
            "name": "Necrolysis",
            "percent": null
        },
        {
            "name": "Hyperpigmentation",
            "percent": null
        }
    ]
}